Definium Therapeutics plans to submit an NDA for LSD-based psychedelic, DT120 in generalised anxiety disorder (GAD) during H1 2027.

Cell and gene therapies are fuelling new possibilities for rare diseases, turning a field defined by unmet need into one of the industry’s most dynamic areas of innovation.

A survey of 175 pharma executives highlights an increasing reluctance to launch in lower-value markets, alongside a heightened focus on RWE.

Encoded Therapeutics has raised $275m in a Series F financing round to advance development of its disease-modifying therapy (DMT) for Dravet syndrome, with an eye also on initiati ...

ABEC is to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process equipment.

At ERS 2026, investigators reported their findings from their review of the Oxford Asthma Attack Risk Scale Meta-Analysis (ORACLE2).

Though yet to be finalised, the initial recommendation would mean the injectable PrEP would not be covered on the NHS.

Biotechs and investors are increasingly altering their strategies amid changes in the development and commercial landscape.

Thoracic oncologists previously touted the potential of Bayer's Hyrnuo in HER2-mutant NSCLC in both the first- and second-line settings.

Biomedicines investigators presented pharmacodynamics and safety results from the company’s ongoing Phase I study (NCT07116889) evaluating GB-0895.

Cheplapharm will acquire production sites in Hungary, Singapore and France. Credit: Gorodenkoff / Shutterstock.com. Cheplapharm has entered a strategic partnership to take over a portfolio of 20 ...

While Novo Nordisk will remain its legal name, the change means Novo will be its front-facing identifier alongside its trusted Apis bull. Credit: Novo. When Mike Doustdar joined Novo Nordisk as CEO, ...